Patents Examined by J. S. Parkin
  • Patent number: 7862994
    Abstract: This invention provides agents determined to be capable of inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+cell and agents determined to be capable of inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4+cell. This invention also provides methods to identify such agents. This invention further provides methods of inhibiting fusion of a macrophage-tropic primary isolate of HIV-1 with a CD+ cell and methods of inhibiting fusion of a T cell-tropic isolate of HIV-1 with a CD4+cell susceptible to infection by a T cell-tropic isolate of HIV-1.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: January 4, 2011
    Assignee: Progenics Pharmaceuticals Inc.
    Inventors: Graham P. Allaway, Virginia M. Litwin, Paul J. Maddon
  • Patent number: 7838001
    Abstract: Synthetic peptides of the monomer type with 13 to 33 amino acids, in linear form or in a form cyclized by means of inter-cysteine disulphide bridges, have the general formula (I): ?-Z-TrpGlyCys-?-CysTyrThrSer-???(I) wherein ? is a biotinyl radical, a biocytinyl radical, a hydrogen atom, an acetyl (CH3CO—) radical, an aliphatic chain which may contain one or two thiol, an aldehyde functional group, or an amine functional group, Z represents peptide sequence -?1-Ser-?2-, -?1-Gln-?2-, or -?1-Asn-?2-, wherein -?1 represents a peptide sequence of 0 to 9 amino acids and -?2 represents a peptide sequence of 0 to 5 amino acids, ?is -Arg Gly Arg Leu Ile-(SEQ ID NO: 15), -Arg Gly Arg Leu Val-(SEQ ID NO: 16), -Arg Gly Lys Leu Ile-(SEQ ID NO: 17), -Arg Gly Lys Leu Val-(SEQ ID NO: 18), -Lys Gly Arg Leu Ile-(SEQ ID NO: 19), or -Lys Gly Arg Leu Val-(SEQ ID NO: 20), ?, attached to the —CO— group of serine, is a hydroxyl (—OH) radical, an amino (—NH2) radical, an alkoxy radical having 1 to 6 carbon atoms, a peptide sequence
    Type: Grant
    Filed: April 13, 2006
    Date of Patent: November 23, 2010
    Assignee: Bio-Rad Pasteur
    Inventors: Denis Marie Bernard Chenebaux, Jean-Francois Hubert Delagneau, Stephane Jean Xavier Gadelle, Francois Yves Rieunier
  • Patent number: 7777020
    Abstract: This invention encompasses an env nucleic acid product produced by a process comprising providing a sample containing HIV-1 nucleic acid and amplifying the nucleic acid using primer pairs.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: August 17, 2010
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
    Inventors: Maurice Moncany, Luc Montagnier
  • Patent number: 7777011
    Abstract: Synthetic polypeptides having at least one antigenic site of a prior protein, methods for their use and manufacture, antibodies raised against such polypeptides and diagnostic kits containing these polypeptides or antibodies.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: August 17, 2010
    Assignee: Protherics Medicines Development Limited
    Inventors: Robert Vincent Fishleigh, Barry Robson, Roger Paul Mee
  • Patent number: 7767800
    Abstract: A variant of a LAV virus, designated LAVMAL and capable of causing AIDS. The cDNA and antigens of the LAVMAL virus can be used for the diagnosis of AIDS and pre-AIDS.
    Type: Grant
    Filed: April 17, 2003
    Date of Patent: August 3, 2010
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
  • Patent number: 7759477
    Abstract: The invention relates to polypeptide fragments of HIV-1, HIV-2, and SIV, antibodies that bind to the polypeptides of the invention, methods of using the antibodies, and kits containing the antibodies. The invention also relates to polynucleotides that encode the polypeptide fragments of the invention.
    Type: Grant
    Filed: June 8, 2004
    Date of Patent: July 20, 2010
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
    Inventors: Maurice Moncany, Luc Montagnier
  • Patent number: 7731975
    Abstract: Chimeric GP molecules were constructed which contain portions of both the EBOV and MBGV GP proteins by swapping the subunits between EBOV and MBGV. The chimeric molecules were cloned into an alphavirus replicon which offers the advantage of high protein expression levels in mammalian cells and is a proven vaccine vector. These chimeric molecules fully protected guinea pigs from MBGV challenge, and conversely protected the animals from EBOV challenge. These results indicate that a protective epitope resides within the GP2 subunit of the MBGV GP protein and at least partially within the GP2 subunit of the EBOV GP protein. Additionally these results show that a construction of a single-component bivalent vaccine protective in guinea pigs is achievable.
    Type: Grant
    Filed: January 31, 2002
    Date of Patent: June 8, 2010
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: Case C. Grogan, Michael C. Hevey, Alan L. Schmaljohn
  • Patent number: 7638269
    Abstract: A cell-free method for translation and assembly of viral capsid and capsid intermediates is disclosed. Also disclosed are novel capsid assembly intermediates and novel host proteins which bind to such assembly intermediates. The invention also includes a screening method for compounds that alter viral capsid assembly, and a method of treating viral infection using compounds which inhibit the capsid assembly pathway.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: December 29, 2009
    Assignees: The Regents of the University of California, The University of Washington
    Inventors: Jaisri R. Lingappa, Kevin C. Klein, Vishwanath R. Lingappa
  • Patent number: 7585508
    Abstract: Novel hybrid fusion peptides are disclosed. The novel peptides are formed by the fusion of two or more components. One component is a peptide sequence or variant of a peptide sequence derived from a malaria parasite merozoite peptide which has affinity for and binding capability to red blood cells. In particular segments of the glycophorin binding peptide 130 (GBP130), are preferred for the first component. Also disclosed are alternative first components, the glycophorin binding peptide homologues (GBPH), or the erythrocyte binding antigen 175 (EBA175), or the plasmodium vivax Duffy receptor or the pre major merozoite surface antigen PMMSA or the (P200) peptide. The first component peptide is fused to all or part of a peptide segment derived from the CD4 molecule or part thereof or variant thereof which shows binding affinity for the HIV virus.
    Type: Grant
    Filed: March 10, 1993
    Date of Patent: September 8, 2009
    Inventor: Kenneth F. Prendergast
  • Patent number: 7575750
    Abstract: This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections.
    Type: Grant
    Filed: September 23, 2003
    Date of Patent: August 18, 2009
    Assignee: Frontiers Biotechnologies Col, Ltd.
    Inventors: Dong Xie, He Jiang
  • Patent number: 7566529
    Abstract: A method of recovering an enzyme activity, such as reverse transcriptase (RT) activity, from enveloped viruses, such as HIV, in a biological sample containing a non-protected enzymes, is described. A cysteine-modifying substance is used to destroy the activity of the non-protected enzymes, followed by removal of the enveloped virus particles or inactivation of the cysteine-modifying substance with a chemical. Then the virus envelope is lysed and the released enzymes are recovered. Commercial packages containing written and/or data carrier instructions and some chemicals for performing laboratory steps for recovery of an enzyme activity from enveloped viruses, are also disclosed.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: July 28, 2009
    Assignee: Cavidi Tech AB
    Inventors: Clas Källander, Simon Gronowitz, Tommy Gatu
  • Patent number: 7556814
    Abstract: An antigenic and immunogenic composition of predetermined inactivated strains of human immunodeficiency virus (HIV) is disclosed. Inactivation is through psoralen and ultraviolet radiation; the composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement Factor H. Determination of strains for inactivation may be though immunotherapeutic genotyping or probabilistic assessment of risk of exposure.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: July 7, 2009
    Inventor: Nelson M. Karp
  • Patent number: 7521176
    Abstract: Methods in accordance with the present invention involve novel measurements of the disease status of hosts infected with the human immunodeficiency virus. In particular, the present invention relates to a measurements of the numbers in a sample volume of (a) productively HIV-infected cells and (b) cells capable of being infected by HIV, e.g., cells expressing CD4, CCR5, and/or CXCR4. These two values can be represented as a single ratio, e.g., number of productively infected cells/number of cells capable of being infected by HIV, and can be utilized as an indicator of disease status, such as disease progression, viral replication, etc.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: April 21, 2009
    Assignee: Theranostech, Inc.
    Inventors: Robert A Hallowitz, John Krowka, Shawn Matlock
  • Patent number: 7390624
    Abstract: The invention concerns a process for the production of metal chelate-labelled peptide antigens, peptides obtainable by this process and their use in an immunological method of detection.
    Type: Grant
    Filed: February 10, 2003
    Date of Patent: June 24, 2008
    Assignee: Roche Diagnostics GmbH
    Inventors: Christoph Seidel, Ursula-Henrike Wienhues, Eva Höss
  • Patent number: 7378265
    Abstract: The present invention relates to a method of inactivating enveloped viruses in a viral preparation predominantly containing non-enveloped viruses by the action of a solvent at a temperature of between ?5° C. and +50° C. and at a pH of between about 5 and 9. Its subject is also a method of preparing a viral preparation comprising such a method of inactivation. The invention also relates to a viral preparation obtained according to the method of the invention. Finally, it relates to a host cell and a composition comprising such a viral preparation as well as their uses for therapeutic or prophylactic purposes.
    Type: Grant
    Filed: December 12, 2005
    Date of Patent: May 27, 2008
    Assignee: Transgene S.A.
    Inventors: David Gaillac, Michel Koehl
  • Patent number: 7344722
    Abstract: The cold-adapted master strain A/Ann Arbor/6/60 7PI (H2N2) and progenitor wild type E2(3) viral strains have been deposited and their genomic sequences identified. Seven nucleotide differences were found between the sequences identified herein and the previously published sequences for cold-adapted A/Ann Arbor/6/60 genes. The cold-adapted live influenza virus of the present invention can be reassorted with a variety of epidemic wild type influenza viruses and used to produce vaccines to prophylactically and therapeutically treat influenza.
    Type: Grant
    Filed: December 14, 1995
    Date of Patent: March 18, 2008
    Assignee: The Regents of the University of Michigan
    Inventors: Hunein F. Maassab, Martha Louise Herlocher
  • Patent number: 7335363
    Abstract: The present invention is directed to genetically engineered, membrane-enveloped viruses with deletion mutations in the protein transmembrane domains. Also provided are viral vaccines based on the engineered viruses, methods of producing and using such vaccines.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: February 26, 2008
    Assignee: Research Development Foundation
    Inventors: Racquel Hernandez, Dennis T. Brown
  • Patent number: 7323183
    Abstract: There is provided vaccine compositions for intranasal administration, which compositions comprise one or more antigens and an effective adjuvant amount of a chitosan.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: January 29, 2008
    Assignee: Archimedes Development Limited
    Inventors: Lisbeth Illum, Steven Neville Chatfield
  • Patent number: 7291452
    Abstract: The invention concerns nucleic acids derived from human V9 erythrovirus, fragments thereof, encoded polypeptides, and applications as diagnostic reagents and as immunogenic agents.
    Type: Grant
    Filed: December 3, 1998
    Date of Patent: November 6, 2007
    Assignee: Assistance Publique Hopitaux de Paris
    Inventors: Quang Tri Nguyen, Antoine Garbarg-Chenon, Véronique Auguste
  • Patent number: 7223410
    Abstract: An immunogenic composition capable of producing a respiratory syncytial (RS) virus specific immune response in a host immunized therewith comprises purified, inactivated RS virus which is substantially free from cellular and serum components and which is non-infectious, non-immunopotentiating, immunogenic and protective. The virus is grown on a vaccine quality cell line and harvested virus is purified under non-denaturing conditions to be substantially free from cellular and serum components. The purified RS virus is inactivated using ?-propiolactone, a non-ionic detergent, particularly n-octyl-?-D-glucopyranoside and n-octyl-?-D-glucopyranoside, or ascorbic acid. The immunogenic composition may be formulated as a vaccine for in vivo administration to a human host. The immunogenic composition also may be used in diagnostic applications.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: May 29, 2007
    Assignee: Sanofi Pasteur Limited
    Inventors: Sonia E. Sanhueza, Mary Elizabeth Ewasyshyn, Michel Henri Klein